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Influence of hemoperfusion on the concentration of f3-methyl-
digoxin and hormones in plasma. The influence of hemoperfusion
with cellulose acetate-coated charcoal column (Adsorba C, Gam-
bro) on plasma concentration of several bioactive substances
was studied in 13 patients with chronic renal insufficiency. The
serum f3-methyldigoxin, aldosterone, 25-hydroxyvitamin D, tn-
iodothyronine, thyroxine, gastrin, insulin, PTH, human growth
hormone, and PRA were measured during hemoperfusion at the
inlet and outlet of the charcoal column. The results show that
charcoal hemoperfusion is an effective procedure for removing
/3-methyldigoxin from blood. The plasma aldosterone, 25-hy-
droxyvitamin D, triiodothyronine, thyroxine, insulin, and PTH
were adsorbed by the column with an approximate clearance rate
of 40 mI/mm and a blood flow rate of 200 mllmin. The results
suggest that adsorption of protein hormones may be limited by
the size of hormone molecule, whereas high affinity binding to
plasma proteins may limit the adsorption of lower molecular
weight substances (below 800 daltons). After 3 hours of hemo-
perfusion a significant decrease of human growth hormone, al-
dosterone, 25-hydroxyvitamin D, triiodothyronine, and thyrox-
ine concentrations in systemic blood was observed. PRA did not
change, but insulin and PTH concentrations somewhat increased
after hemoperfusion. The results suggest that a significant deple-
tion occurred for those substances which have a relatively slow
turnover rate in plasma. Long-term use of hemoperfusion would
require a detailed control of possible effects on the endocrine and
vitamin status of patients.
Influence de l'hémoperfusion sur les concentrations plasma-
tiques de f3-méthyldigoxine et de diverses hormones. Chez 13 mal-
ades atteints d'insuffisance rénale chronique l'influence de
l'hdmoperfusion au moyen de colonnes de charbon enrobdes
d'acdtate de cellulose (Adsorba C, Gambro) sur les concentra-
tions plasmatiques de diverses substances biologiquement ac-
tives a été étudiée. Les concentrations sériques de Ia /3-methyl-
digoxine, l'aldosterone, Ia 25-hydroxyvitamine D, la triiodothy-
ronine, la thyroxine, Ia gastrine, l'insuline, Ia parathormone,
I'hormone de croissance ont été mesurées, de méme que
l'activitC rdnine plasmatique, au cours de l'hémoperfusion, a
l'entrCe et a Ia sortie de Ia colonne de charbon. Les résultats
montrent que l'hemoperfusion est un procedé efficace de sous-
traction de Ia 3-méthyldigoxine. L'aldostErone, la 25-hydroxy-
vitamine D, la tniiodothyronine, Ia thyroxine, l'insuline et
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l'hormone parathyroidienne sont adsorbées par Ia colonne avec
des clairances de l'ordre de 40 mI/mm pour des debits de sang de
200 mI/mm. Les résultats suggèrent que l'adsorption d'hormones
protéiques peut étre limitde par Ia taille de Ia molecule hormo-
nale alors que Ia haute affinité de liaison aux protéines plasma-
tiques peut limiter l'adsorption de substances de faibles poids
moléculaires (inférieurs a 800 daltons). Après 3 heures
d' hémoperfusion une diminution significative des concentrations
de l'hormone de croissance, de l'aldostdrone, de Ia 25-hydroxy-
vitamine D, de Ia triiodothyronine et de Ia thyroxine dans le sang
circulant est observée. L'activitd rdnine plasmatique ne change
pas et l'insuline et Ia parathormone augmentent après
I'hemopenfusion. Ces résultats suggérent qu'une déplétion sig-
nificative des substances dont le turnover plasmatique est lent
est réalisée. L'emploi au long coors de l'hemoperfusion exigerait
un contrôle ddtaillC des effets endocriniens et vitaminiques pos-
sibles chez ces malades.
Charcoal hemoperfusion has been successfully
used in the treatment of acute drug overdosage [1-
6], hepatic coma [4, 7—12], and terminal renal failure
combined with hemodialysis [13, 14]. Activated
charcoal is known to adsorb strongly various com-
pounds, and the spectrum of solutes removed from
blood after contact with hemoperfusion column at
present is characterized incompletely. It has been
reported that the plasma creatinine, uric acid, phe-
nolic derivatives, guanidines, urea, amino acids,
and "middle molecular weight substances" are
reduced in concentration after charcoal hemo-
perfusion. Although cellulose acetate encapsulation
of charcoal particles introduces some degree of
selectivity to adsorption characteristics, hemo-
perfusion still may result in a nonselective loss of
biologically active substances, some of which are
vital constituents of human blood. The present
study aimed to establish the influence of charcoal
hemoperfusion on the plasma level of /3-methyl-
digoxin, thyroxine, triiodothyronine, aldosterone,
25-hydroxycholecalciferol, parathyroid hormone
(PTH), insulin, gastrin, human growth hormone,
and plasma renin activity (PRA).
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Methods
Thirteen patients with chronic renal failure (4
women, 9 men), one patient with acute liver failure,
and one patient with acute phenobarbital intoxica-
tion were examined. The mean age of all patients
studied was 35 years (range, 20 to 51). All patients
with chronic renal insufficiency were on regular
dialysis treatment. The site of blood access in each
of these patients was a Cimino-Brescia arterioven-
ous fistula, whereas in each of two other patients, a
Quinton-Scribner silastic-teflon shunt was intro-
duced. The Adsorba C column (Gambro) used for
hemoperfusion in this study contained 300 g of acti-
vated charcoal particles encapsulated in cellulose
acetate membranes of 3 to 5 jsm thickness. Accord-
ing to Chang [2], the clearance of creatinine and the
clearance of uric acid by this column both exceed
100 mllmin at blood flow rates of 200 mllmin, where-
as platelet depletion has been estimated as to 4 to
10% of the preperfusion level.
Initial venous blood samples were taken before
connection of the hemoperfusion circuit to the pa-
tient's circulation. Next, a bolus injection of /3-
methyldigoxin (Lanitop®, Boehringer, Mannheim)
was administered i.v., followed by heparin, 10,000
IU. Five minutes later, hemoperfusion was started
at a blood flow rate of 200 mi/mm. Further heparin
doses (2500 IU) were given to maintain the Lee-
White clotting time between 20 and 30 mm. At 30
and 180 mm of hemoperfusion, blood samples were
taken at the inlet (designed 1A and 2A) and at the
outlet (1P and 2P) of the hemoperfusion column. All
blood samples were centrifuged within 5 mm after
collection, and the plasma was separated and stored
at —18° C for further analyses. Hemoperfusion was
performed in fasting patients, usually in the morn-
ing. Three patients were studied on two separate
occasions.
The f3-methyldigoxin was measured with the
Digoxin-125J set (Boehringer, Mannheim, FRG).
The triiodothyronine was estimated by radioimmu-
noassay with TRI-SET reagents (Centre of Produc-
tion and Distribution of Isotopes, wierk, Poland),
and thyroxine by the DATA-Tope1T4 procedure
(reagents supplied by DADE, Pharmacia Labs Inc.,
Piscataway, New Jersey 08854, USA). The aldoste-
rone [15], PRA [15], and human growth hormone
[16] were determined by radioimmunoassay as pre-
viously described. Insulin was measured by radio-
immunoassay [17] with minor modifications. Gas-
trin was determined by radioimmunoassay [18] with
gastrin G-17 as standard and as tracer. The serum
immunoreactive PTH was measured by radioimmu-
noassay [19], with purified bovine PTH (1-84) as
standard and 1251-bovine PTH (1-84) as tracer.
Serum 25-hydroxyvitamin D was determined by the
radiocompetitive assay of Preece et al [20].
Results
/3-methyldigoxin. As shown in Fig. 1, /3-methyl-
digoxin is effectively removed from blood plasma
not only at 30 mm of hemoperfusion when plasma
concentrations were high (average adsorption of
65% of circulating glycoside on single pass) but also
in the third hour of hemoperfusion when moderate
concentrations were present in the circulating
blood. The average clearance rate of /3-methyl-
digoxin by the charcoal column in 16 patients was
131.0 (sEM) 7.1 mi/mm at 30 mm and 77.0 13
mi/mm at 180 mm of hemoperfusion (Table 2).
Aldosterone. Aldosterone was effectively re-
moved from plasma by the charcoal column in 10
out of 14 patients studied, with an average clear-
ance rate of 50.9 14.3 ml/min at 30 mm and 34.6
12.3 mI/mm at 180 mm of hemoperfusion. In spite of
this, during 3 hours of hemoperfusion the plasma
aldosterone concentration decreased only marginal-










Inlet Outlet Inlet Outlet
30mm 180mm
Fig. 1. Inlet (I) and outlet (0) plasma -methyldigoxin concen-
trations at 30 miii (left) and 180 mm (right) of hemoperfusion
after iv. administration of Lanitop.
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°Values are SEM. Significance of differences were calculated by the Wilcoxon test:
BP < 0.10 compared with basal values.
Cp < 0.05 compared with basal values.
p < 0.01 compared with basal values.
25-Hydroxy vitamin D. 25-Hydroxyvitamin D (25-
OH-D) decreased to 78% of the preperfusion level
by 30 mm, and to 66% of the preperfusion level by
180 mm of charcoal hemoperfusion. The mean
clearance rate of 25-OH-D by the column was 45.8
10.0 and 50.1 13.8 mI/mm calculated for 30 mm
and 180 mm of hemoperfusion, respectively.
Triiodothyronine (T3). Passage of blood through
the charcoal column was connected with a signifi-
cant decrease of T3 concentration in all subjects
studied (Fig. 2, Tables 1 and 2). The mean clearance
rate by the hemoperfusion column was 39.1 10.2
and 24.8 5.3 ml/min at 30 mm and 180 mm, re-
spectively. During 3 hours of hemoperfusion, the
mean T3 concentration fell from an initial value of
1.37 ng/ml to 1.17 ng/ml at 30 mm and to 0.88 ng/ml
at 180 mm (P < 0.01).
Thyroxine (14). T4 was effectively removed from
blood by the hemoperfusor with a clearance rate of
36.9 13.4 and 44,4 14.6 mi/mm at 30 and 180
mm of hemoperfusion, respectively (Table 2). In pe-
ripheral blood, a decrease of T4 from 16.3 to 11.2
g/di was noted after 3 hours of hemoperfusion
(Table 1).
Immunoreactive gas/nfl (IRG). The results ob-
tained by radioimmunoassay with gastrin G-17 as
tracer and as a standard are shown in Tables 1 and
2. At 30 and 180 mm of hemoperfusion, lower val-
ues of IRG (P < 0.05) in peripheral blood were
noted than were noted at the start of hemo-
perfusion. In the majority of experiments, surpris-
ingly higher values of IRG were found in blood
withdrawn at the outlet rather than at the inlet of the
charcoal column. This resulted in negative hemo-
perfusor clearance rates, calculated according to a
standard formula (—23.2 20.6 and —46.8 17.2
30mm 180mm
Fig. 2. Inlet and (Jut/ct plasma triiodothyronine concentrations at
30 ,nin (left) and 180 mm (right) of hemoperfusion.
mi/mm at 30 and 180 mm, respectively), suggesting
release of immunoreactive material from the char-
coal column.
Immunoreactive insulin (IRI). In the majority of
patients, a significant decrease of IRI in the blood
leaving the charcoal column was found at 30 mm of
hemoperfusion; a smaller drop was observed at 180
mm (Fig. 3). In 3 patients, however, the IRI in post-
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Table 2. Clearance of hormones and bioactive substances by the charcoal column measured after 30 mm and 180 mm of hemoperfusion
Hormone (drug)
Mol wt
daltons tt Percent boundin plasma' Hemoperfusion clearance rateami/mm




































131.0 7.1 77.0 13.0
50.9 14.3 34.6 12.3
45.8 10.0 50.1 13.8
39.1 10.2 24.8 5.3
36.9 13.4 44.4 14.6
—23.2 20.6 —46.8 17.2
46.5 14.1 37.3 16.9
38.0 6.5 44.5 8.2
15.6 18.3 — 3.4 18.2
47.5 16.9 —36.6 28.2
aValues are SEM.







entering the column. The mean clearance rate of
IRI by the column was 46.5 14.1 mi/mm at 30 mm
and 37.3 16.9 mi/mm at 180 mm of hemo-
perfusion. Despite this adsorption of IRI by the
charcoal column, the mean IRI level in peripheral
blood after hemoperfusion was higher (P < 0.10)
than it was at the starting point (Table 1).
Immunoreactive parathyroid hormone (iPTH).
As can be seen from Fig. 4, passage of blood
through the charcoal column was followed by a sig-
nificant adsorption of iPTH. Despite a mean clear-
ance rate of 38.0 6.5 and 44.5 8.2 mI/mm by the
column at 30 and 180 mm of hemoperfusion, respec-
tively, a moderate increase (P < 0.10) of this hor-
mone in peripheral blood was found after hemo-
perfusion (Tables 1 and 2).
Immunoreactive human growth hormone (iHGH).
During a perfusion period of 3 hours, a significant
decrease of iHGH in peripheral blood was noted
(Table 1), although in 4 out of 14 patients an appar-
ent increase of iHGH was seen. Extraction of
iHGH from blood plasma by the charcoal column
was not statistically significant. The mean clearance
rate of iHGH by the hemoperfusor was 15.6 18.3
mi/mm at 30 mm and —3.4 18.2 mI/mm at 180
mm.
Plasma renin activity (PRA). PRA did not change
significantly in peripheral blood during 3 hours of
hemoperfusion, despite a significant decrease of
PRA after contact with the column at 30 mm. The
mean clearance rate of PRA by the charcoal column
was 47.5 16.9 mI/mm at 30 mm, but it was —36.6
28.2 mi/mm at 180 mm of hemoperfusion.
Discussion
The data in Table 2 show that most substances
measured in the present study (excluding gastrin
and the two higher molecular weight hormones)
were cleared effectively by the charcoal column
from the blood plasma. The spectrum of substances
measured in this study covered the range of molecu-
lar weights from 360 to about 43,000 daltons. Dex-
tran-coated charcoal has been widely used for in
vitro adsorption of hormones. This technique has
been found effective for a number of "middle mo-
50-
10-
Inlet Outlet Inlet Outlet
20mm 180 mm
Fig. 3. Inlet and outlet plasma insulin concentrations at 30 mm
(left) and 180 mm (right) of hemoperfusion.






lecular weight substances", including gastrin, in-
sulin, angiotensins I and II, PTH [23], and poiy-
peptides of the size of human growth hormone and
gonadotropins may also be adsorbed to charcoal in
vitro, although with lesser capacity. On the other
hand, in vitro adsorption of immunoglobulins G and
steroid-binding proteins by charcoal is small and
may be minimized by suitable coating of sorbent
particles [23]. Insulin and iPTH have been ef-
fectively cleared from blood plasma during charcoal
hemoperfusion, whereas the clearance rate of
iHGH was negligible. Divergent results obtained for
PRA may suggest that some renin may initially get
adsorbed on the surface of encapsulated charcoal
particles and later released into the perfusing blood.
Thus, the data in Table 2 seem to suggest that ad-
sorption of proteins larger than 20,000 daltons is
probably not significant, whereas smaller poly-
peptides are removed with an approximate clear-
ance rate of 40 mI/mill.
Results obtained with gastrin measurements sur-
prisingly suggested some release of IRG into the
perfused blood. Similar observations were made al-
so in some patients for plasma iHGH and IRI,
where also in some patients outflow concentrations
of hormone exceeded inflow levels. Several pos-
sible explanations exist for these findings. Protein
hormones may be adsorbed by the column at the
beginning of perfusion and released later, possibly
displaced by other substances present in higher
concentration or possessing higher affinity to sur-
face sites of activated charcoal particles. Insulin,
gastrin, and human growth hormone are circulating
in several forms of different molecular weight. The
large molecular forms usually have smaller biologic
activity and may also crossreact poorly with stan-
dard immunoassay systems which utilize antisera
raised against mature hormonal molecules. In this
study, the synthetic 17-amino acid gastrin sequence
was used as a standard, as well as immunogen.
Higher outlet gastrin concentrations might possibly
have been produced by splitting of big-gastrin into
the more immunoreactive small molecular forms
during the passage of blood through the charcoal
column.
Results of this study indicate that all tested sub-
stances of molecular weight between 360 and 780
daltons have been effectively cleared by the hemo-
perfusion column, confirming earlier suggestions
from in vitro recirculation experiments [7, 22]. Dif-
ferences in magnitude of clearance rate seem to be
roughly related to the polarity of hormone molecule
and inversely proportional to its high affinity bind-
ing by the specific plasma proteins. The low affinity
of /3-methyldigoxin to plasma proteins (less than
30% protein-bound) may explain the highest clear-
ance rate of this drug by the charcoal column. Rela-
tively high hemoperfusion clearance rates, how-
ever, have been reported also for digitoxin (about
40 ml/min), which is approximately 93% protein
bound in human plasma [21]. Intermediate hemo-
perfusion clearance rates have been found for al-
dosterone and 25-OH-D, which are about 70% and
90% protein-bound, respectively, whereas lower,
but still significant, extraction by the column has
been established for both thyroid hormones which
are almost totally bound to thyroxine-binding pro-
teins of plasma (Table 2).
Removal of bioactive substances should not be-
come a major problem in short-term treatment of
acute intoxication. Where secondary shifts from
other compartments could theoretically compen-
sate for the loss of a substance from the plasma
pooi. Use of hemoperfusion in the repetitive treat-
ment of terminal renal failure by itself or combined
with hemodialysis or ultrafiltration [3, 13, 14] would
require a more detailed study of effects of endocrine
and vitamin status of patients. From theoretical
considerations one should expect a significant de-
3-
2-
Inlet Outlet Inlet Outlet
30mm 180 mm
Fig. 4. Inlet and outlet plasma PTH concentrations at 30 mm
(left) and 180 mm (right) of hemoperfusion.
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pletion of those substances which have relatively
slow turnover rates or metabolic clearance rates
compared with hemoperfusion clearances. This
view seems to be confirmed by the results shown in
Table 1. Hemoperfusion of 3 hour's duration caused
in this study a significant and gradual decrease in
serum 25-OH-D, T4, and T3, which have serum t1/2
of 21 days, 7 days, and 27 hours, respectively.
There was some decrease in plasma aldosterone (P
< 0.10), which has a rather high metabolic clear-
ance rate of about 1000 mi/mm and a comparatively
short t'/2 of 30 mm. On the other hand, no system-
atic decrease in circulating concentration was noted
for insulin, iPTH, and PRA, which agrees well with
the fact that all these hormones have short half-
lives, high secretion rates, and high metabolic clear-
ance rates, compared with hemoperfusor clearance.
There was a decrease in human growth hormone
concentration, but it is difficult to exclude that the
initial values were biased by the stress-induced re-
lease of this hormone. Increases in average PTH
and insulin concentrations after hemoperfusion (P
<0.10) might have been caused by increased secre-
tion of these hormones stimulated by other factors
related to the therapeutic procedure itself. As char-
coal hemoperfusion has been reported to produce
hypocalcemia 11, 21], direct stimulation of para-
thyroid glands may explain the observed increase in
circulating iPTH.
In summary, charcoal hemoperfusion by Ad-
sorba-C column is an effective procedure of remov-
ing f3-methyldigoxin from blood plasma. Plasma
concentrations of 25-OH-D, aldosterone, T3, T4,
PTH, and insulin are significantly decreased after a
single passage of blood through the charcoal col-
umn. After 3 hours of hemoperfusion, significant
decreases in human growth hormone, aldosterone,
25-OH-D, T3, and T4 concentrations in systemic
blood have been observed. It should be empha-
sized, however, that the results may vary with other
types of adsorbents and coating materials.
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